This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).

PHASE1CompletedINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

July 12, 2025

Study Completion Date

July 12, 2025

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

DRUG

Bmab 1200 (Biosimilar Ustekinumab)

Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose

Trial Locations (1)

Lambda Therapeutic Research Ltd, Ahmedabad